Edwards Lifesciences
1,196 hedge funds and large institutions have $31.9B invested in Edwards Lifesciences in 2024 Q3 according to their latest regulatory filings, with 141 funds opening new positions, 370 increasing their positions, 500 reducing their positions, and 227 closing their positions.
147% more call options, than puts
Call options by funds: $733M | Put options by funds: $296M
1.88% less ownership
Funds ownership: 81.93% → 80.05% (-1.9%)
8% less funds holding
Funds holding: 1,297 → 1,196 (-101)
16% less capital inflows, than outflows
Capital inflows: $5.39B | Capital outflows: $6.44B
26% less repeat investments, than reductions
Existing positions increased: 370 | Existing positions reduced: 500
38% less first-time investments, than exits
New positions opened: 141 | Existing positions closed: 227
60% less funds holding in top 10
Funds holding in top 10: 15 → 6 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.06B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$655M |
| 3 |
Ninety One (UK)
London,
United Kingdom
|
+$501M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$266M |
| 5 |
BlackRock
New York
|
+$262M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$971M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$652M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$487M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$419M |
| 5 |
Janus Henderson Group
London,
|
-$303M |
EW Hedge Fund Activity: Q3 2024 in Review
1,196 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2024, worth a combined $31.9B — down 30% from $45.6B a quarter earlier.
Sellers outnumbered buyers: 227 funds closed out of EW and 141 opened new positions — a net loss of 86 holders — while 500 trimmed existing stakes and 370 added.
The largest buyer was Wellington Management Group, adding an estimated $1.06B. The largest seller was AllianceBernstein, cutting an estimated $971M.
- 1,196 institutional investors held Edwards Lifesciences (EW) as of Q3 2024, down from 1,297 in Q2 2024.
- Funds reported $31.9B of Edwards Lifesciences stock for Q3 2024, down 30% quarter-over-quarter.
- 141 funds opened new Edwards Lifesciences positions in Q3 2024 and 227 closed out, a net change of -86 holders.
- The largest Edwards Lifesciences buyer in Q3 2024 was Wellington Management Group, an estimated $1.06B added.
- The largest Edwards Lifesciences seller in Q3 2024 was AllianceBernstein, an estimated $971M sold.
Based on aggregated 13F filings for Q3 2024.